Form 603, “Notice of initial substantial holder” was lodged with the Australian Securities Exchange on 30th January at 5:25 PM.
View the Form 603.
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 3, 2026
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)